Title |
The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments
|
---|---|
Published in |
Frontiers in immunology, May 2017
|
DOI | 10.3389/fimmu.2017.00631 |
Pubmed ID | |
Authors |
John P. Veluchamy, Nina Kok, Hans J. van der Vliet, Henk M. W. Verheul, Tanja D. de Gruijl, Jan Spanholtz |
Abstract |
Natural killer (NK) cells are critical immune effector cells in the fight against cancer. As NK cells in cancer patients are highly dysfunctional and reduced in number, adoptive transfer of large numbers of cytolytic NK cells and their potential to induce relevant antitumor responses are widely explored in cancer immunotherapy. Early studies from autologous NK cells have failed to demonstrate significant clinical benefit. In this review, the clinical benefits of adoptively transferred allogeneic NK cells in a transplant and non-transplant setting are compared and discussed in the context of relevant NK cell platforms that are being developed and optimized by various biotech industries with a special focus on augmenting NK cell functions. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 1 | 11% |
Germany | 1 | 11% |
Venezuela, Bolivarian Republic of | 1 | 11% |
United States | 1 | 11% |
Switzerland | 1 | 11% |
Unknown | 4 | 44% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 6 | 67% |
Scientists | 3 | 33% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Germany | 1 | <1% |
Unknown | 270 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 48 | 18% |
Student > Ph. D. Student | 42 | 15% |
Student > Master | 30 | 11% |
Other | 22 | 8% |
Student > Bachelor | 17 | 6% |
Other | 29 | 11% |
Unknown | 83 | 31% |
Readers by discipline | Count | As % |
---|---|---|
Immunology and Microbiology | 50 | 18% |
Biochemistry, Genetics and Molecular Biology | 49 | 18% |
Medicine and Dentistry | 24 | 9% |
Agricultural and Biological Sciences | 22 | 8% |
Pharmacology, Toxicology and Pharmaceutical Science | 10 | 4% |
Other | 28 | 10% |
Unknown | 88 | 32% |